[Translation] A Phase I, randomized, double-blind, placebo-controlled, dose-escalation study to evaluate the pharmacokinetics, immunogenicity, safety, and tolerability of MEDI3506 following a single subcutaneous dose in healthy Chinese subjects
本研究的目的是评价中国健康受试者接受MEDI3506单次皮下给药后的药代动力学、免疫原性、安全性和耐受性。
[Translation] The objectives of this study were to evaluate the pharmacokinetics, immunogenicity, safety, and tolerability of MEDI3506 after a single subcutaneous administration in healthy Chinese subjects.